Cediranib Plus FOLFOX/CAPOX Versus Placebo Plus FOLFOX/CAPOX in Patients With Previously Untreated Metastatic Colorectal Cancer: A Randomized, Double-Blind, Phase III Study (HORIZON II)
Paulo M. Hoff(Translational Research in Oncology), Mark Saunders(Manchester Academic Health Science Centre), Andreas Hochhaus(Jena University Hospital), Ying Cheng(Jilin Province Tumor Hospital), Anitra Fielding(AstraZeneca (United States)), Tamás Pintér(Goethe University Frankfurt), Krassimir Koynov(Instituto do Câncer do Estado de São Paulo), Laura A. Pike(Instituto do Câncer do Estado de São Paulo), Niall C. Tebbutt(Austin Health), Tae Won Kim(Asan Medical Center), Bernhard C. Pestalozzi(University of Zurich), Jane Robertson(Cancer Research UK), Brigitte Van Eyll(Apple (Israel)), G. Kurteva(University Specialized Hospital for Active Treatment of Endocrinology), Jin Li(Johns Hopkins University)
Cited by 154
Related Papers
The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms
|Leukemia|2022|3.8k
Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.7k
<i>K-ras</i> Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer
|New England Journal of Medicine|2008|3.6k
Cetuximab for the Treatment of Colorectal Cancer
|New England Journal of Medicine|2007|1.8k